Clinical trials: Positron Emission Tomography
Neuroendocrine Tumors
Applying PET/MR in Neuroendocrine Tumors - Imaging Dynamic Processes in Both Modalities
Neuroendocrine tumors (NET's) are characterized, among other features, by presence of high concentration of somatostatin receptors.
- Trial name
- NCT04152928
- Testing
- PET/MR scan
- Volunteers
- 50 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Neuroendocrine Tumors
PET/CT Imaging of uPAR-expression in Patients With Neuroendocrine Tumors Using 68Ga-NOTA-AE105
The aim of this non-randomised, prospective study is to investigate the applicability and prognostic value of uPAR PET/CT with the radioligand 68Ga-NOTA-AE105 in patients with neuroendocrine tumors (NETs).
- Trial name
- NCT03278275
- Testing
- One injection of 68Ga-NOTA-AE105, PET/CT
- Where
- Denmark
- Volunteers
- 116 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Parkinsonian Syndrome
Study of Individuals With Parkinson's Symptoms But in Whom There is Diagnostic Uncertainty
The overall goal of this study is to evaluate the use of dopamine transporter (DAT) imaging as a diagnostic tool in subjects with early parkinsonian symptoms, in whom Parkinson's disease (PD) or parkinsonian syndrome (PS) is…
- Trial name
- NCT00129675
- Testing
- [123I]ß CIT
- Where
- United States
- Volunteers
- 169 people
- Sponsor
- Institute for Neurodegenerative Disorders
Cardiac Sarcoidosis, Infective Endocarditis
A Prospective Diagnostic Trial of Al[¹⁸F]F-NOTA-folate PET in Patients With Suspected Cardiac Sarcoidosis and Infective Endocarditis
The goal of this prospective diagnostic study is to evaluate the imaging characteristics, diagnostic performance, radiation dosimetry, and safety of Al[¹⁸F]F-NOTA-folate PET imaging in patients with suspected cardiac sarcoidosis…
- Trial name
- FOL-CARD (NCT07814222)
- Testing
- Al[¹⁸F]F-NOTA-folate PET imaging, [15O]water PET imaging, Echocardiography
- Where
- Finland
- Volunteers
- 143 people, healthy volunteers welcome
- Sponsor
- Turku University Hospital
Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome
Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor
This phase I trial tests the safety, side effects and best dose of NEXI-001 when given with decitabine and lymphodepleting chemotherapy in treating patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that…
- Conditions
- Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome
- Trial name
- NCT06572631
- Testing
- Allogeneic CD8+ Leukemia-associated Antigens Specific T Cells NEXI-001, Biospecimen Collection, Bone Marrow Aspiration
- Volunteers
- healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Breast Cancer, Metastatic Breast Cancer
Radioactive Iodide (131I) Treatment of 124I PET/CT Detected Breast Cancers
This is a treatment protocol designed to accompany the ongoing institutional 124I PET/CT pilot imaging study for patients with invasive breast cancer.
- Trial name
- NCT01360177
- Testing
- 124 PET/CT imaging, Na134I, Tri-iodothyronine
- Where
- United States
- Sponsor
- Stanford University
Chronic Pain
From Nerve to Brain: Toward a Mechanistic Understanding of Spinal Cord Stimulation in Human Subjects
This is a multicenter prospective study of patients who currently have stably implanted spinal cord simulators. Patients will be randomly assigned to turn on or off their spinal cord stimulators for two week intervals up to six…
- Trial name
- NCT05661903
- Testing
- Spinal Cord Stimulator Set to Minimal/No Stimulation Setting, Usual Care, Positron Emission Tomography / Magnetic Resonance Imaging
- Where
- 3 sites in United States
- Volunteers
- 180 people
- Sponsor
- Massachusetts General Hospital
Tumor
68Ga-FAP-RGD PET/CT : Dosimetry and Preliminary Clinical Translational Studies
As an new dual targeting PET radiotracer, 68Ga-FAP-RGD is promising as an excellent imaging agent applicable to various cancers.
- Trial name
- NCT05515783
- Testing
- 68Ga-FAP-RGD
- Where
- China
- Volunteers
- 70 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Healthy
PET Study of Repeated ASN51 in Healthy Volunteers
This is a phase 1, open-label, dose escalation, positron emission tomography (PET) study to investigate the brain occupancy of O-GlcNAcase, and the pharmacodynamics (PD) response in peripheral blood mononuclear cells (PBMCs)…
- Trial name
- NCT05725005
- Testing
- ASN51
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Asceneuron S.A.
Endocrine and Neuroendocrine Tumors
SPECT/CT in Endocrine and Neuroendocrine Tumors
The value of fusion of functional and anatomical data has been described using several fusion techniques for various nuclear medicine procedures and morphologic imaging modalities (SPECT-CT, SPECT-MRI, Coincidence-CT).
- Trial name
- NCT00230139
- Testing
- SPECT/CT
- Where
- Israel
- Volunteers
- 200 people
- Sponsor
- Rambam Health Care Campus
Estrogen Receptor Positive Breast Cancer, Bone Metastases
FDG PET/CT in Breast Cancer Bone Mets
This study will evaluate baseline uptake on a FDG PET/CT scan in patients with breast cancer that has spread to the bones. A repeat FDG PET/CT scan will be done 4 weeks after the start of new breast cancer hormone treatment and…
- Trial name
- NCT01996046
- Testing
- FDG PET/CT scan
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Pennsylvania
Peritoneal Cancer, Peritoneal Metastases
The PIPAC-OPC7 Study: The Use of PET/CT Scans as a Method of Evaluation in Patients Treated With PIPAC, a Pilot Study.
The pilot study will investigate the use of repeated FDG-PET/CT scans in 16 patients with peritoneal metastasis originating from abdominal cancers treated with Pressurized Intraperitoneal Aerosol Chemotherapy.
- Conditions
- Peritoneal Cancer, Peritoneal Metastases, Peritoneal Carcinomatosis, Abdominal Cancer
- Trial name
- NCT06144853
- Testing
- scan
- Where
- Denmark
- Volunteers
- 34 people
- Sponsor
- Odense University Hospital
Cancer, Cardiotoxicity
BIOMARKER and IMAGING CHARACTERISATION of INFLAMMATORY ATHEROMA in PATIENTS RECEIVING IMMUNOTHERAPY and ANGIOGENESIS INHIBITORS
The advent of immunotherapy (immune checkpoint inhibitors [ICI]) has been an extremely important advancement for cancer treatment in recent decades.
- Conditions
- Cancer, Cardiotoxicity, Atherosclerotic Disease
- Trial name
- BIOCAPRI (NCT06597045)
- Testing
- PET/CT with 18-FDG
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- NHS Greater Glasgow and Clyde
Transthyretin Amyloidosis
Evuzamitide in PET/CT to Measure Potential Therapeutic Response in ATTR
This was a single center, prospective cohort study that is evaluating the ability of 124I-evuzamitide PET scanning to detect potential therapeutic changes in subjects under treatment for ATTR after one year had elapsed since…
- Trial name
- NCT05635045
- Testing
- I 124-Evuzamitide
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Columbia University
Aspergillosis and Haematological Malignancy
PET/CT Guided Antifungal Stewardship in Invasive Pulmonary Aspergillosis
OPTIFIL is a pilot prospective multicenter study based over the hypothesis that the normalization of the functional imaging 18F-FDG-PET/CT during the Invasive pulmonary aspergillosis (IPA) could occur earlier than that of…
- Trial name
- OPTIFIL (NCT02955966)
- Testing
- imaging 18F-FDG-PET/CT, Blood collection
- Where
- France
- Volunteers
- 51 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Malignant Breast Neoplasm, Malignant Colorectal Neoplasm
18F-Fluoroazomycin Arabinoside PET-CT in Diagnosing Solid Tumors in Patients
This early phase I trial studies how well 18F-fluoroazomycin arabinoside positron emission tomography (PET)-computed tomography (CT) works in diagnosing solid tumors.
- Conditions
- Malignant Breast Neoplasm, Malignant Colorectal Neoplasm, Malignant Pancreatic Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT03168737
- Testing
- Computed Tomography, Fluorine F 18-fluoroazomycin Arabinoside, Positron Emission Tomography
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- M.D. Anderson Cancer Center
Extramedullary Disease in Multiple Myeloma, Recurrent Multiple Myeloma
Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease
This phase II trial studies how well mezigdomide/carfilzomib/dexamethasone (MeziKD) works in treating patients with multiple myeloma (MM) that has come back after a period of improvement (relapsed) or that does not respond to…
- Conditions
- Extramedullary Disease in Multiple Myeloma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
- Trial name
- NCT06627751
- Testing
- Mezigdomide, Carfilzomib, Dexamethasone
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Roswell Park Cancer Institute
Primary Malignant Liver Neoplasm
Yttrium-90 (Y90) Glass Microspheres PET/CT in Imaging Patients With Liver Tumors
This clinical trial studies how well yttrium-90 (Y90) glass microspheres positron emission tomography (PET)/computed tomography (CT) works in imaging patients with liver tumors .
- Trial name
- NCT03109262
- Testing
- Computed Tomography (CT), Positron Emission Tomography (PET), 90-Yttrium (Y-90) Glass Microspheres
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Stanford University
Prostate Cancer
Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy
This is a multicenter, randomized, open label, phase III study comparing the efficacy and safety of apatulamide combined with concomitant prostate-bed salvage radiotherapy (SRT) and androgen deprivation therapy (ADT) versus…
- Trial name
- CARLHA-2 (NCT04181203)
- Testing
- Apalutamide, Salvage radiotherapy (SRT), Luteinising Hormone Releasing Hormone agonist (LHRHa)
- Where
- 15 sites in France
- Volunteers
- 490 people
- Sponsor
- UNICANCER
Glioma
Evaluation of 18F-fluciclovine (FACBC) PET/MR Uptake in Participants With Glioma
This is a pilot study to assess the ability of [F-18]fluciclovine to differentiate pseudoprogression from progression in participants after therapy, at imaging time points within the 12 week interval post chemoradiation.
- Trial name
- FACBC (NCT04114370)
- Testing
- 18F-fluciclovine
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- James Mountz
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.